Gilead Sciences, Inc. (NASDAQ:GILD) Receives $83.69 Consensus Target Price from Analysts

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have earned an average rating of “Hold” from the eighteen brokerages that are currently covering the company, MarketBeat reports. Eleven analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $83.69.

A number of analysts have commented on GILD shares. Royal Bank of Canada lowered their price target on Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating for the company in a research report on Friday, April 26th. Barclays cut their price target on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a report on Monday, April 29th. Mizuho decreased their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. Finally, UBS Group reduced their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th.

Gilead Sciences Stock Performance

GILD opened at $64.92 on Friday. The firm’s 50-day moving average price is $70.25 and its 200-day moving average price is $75.60. The company has a market cap of $80.83 billion, a P/E ratio of 180.33, a price-to-earnings-growth ratio of 1.31 and a beta of 0.22. The company has a quick ratio of 0.72, a current ratio of 0.98 and a debt-to-equity ratio of 1.08. Gilead Sciences has a 52-week low of $64.33 and a 52-week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. Gilead Sciences’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.37 EPS. As a group, equities analysts anticipate that Gilead Sciences will post 3.74 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.74%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.29% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

Several large investors have recently bought and sold shares of GILD. OFI Invest Asset Management acquired a new position in Gilead Sciences in the 3rd quarter valued at $26,000. Tompkins Financial Corp grew its holdings in shares of Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 241 shares in the last quarter. Fortitude Family Office LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $29,000. Private Wealth Management Group LLC acquired a new position in Gilead Sciences during the fourth quarter worth about $29,000. Finally, Palisade Asset Management LLC purchased a new stake in Gilead Sciences during the 1st quarter valued at about $29,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.